Effect of Rivaroxaban in Thrombosis
Phase 1
- Conditions
- Thrombosis.Other venous embolism and thrombosis
- Registration Number
- IRCT20231021059793N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Age 2-18 years old
CVC-VTE diagnosed by US Doppler
Five days received enoxaparin or heparin
Exclusion Criteria
Active bleeding
History of anaphylaxis to rivaroxaban
Usage of other anticoagulant drugs including ASA, platelet inhibitors, NSAID, Fibrinolytic, SSRI and SNRI
Acutely ill patients with increased risk of bleeding including bronchiectasis, pulmonary cavitation, pulmonary hemorrhage, active cancer, recent HSCT in last 3 months, active GI ulcer or recent GI bleeding in the last 3 months, Liver disease with coagulopathy
Patients needing spinal anesthesia or LP
Creatinine clearance lower than 30 ml/min
Platelet count lower than 75 X 109
Dialysis catheter or artificial heart leaflet
Unstable hemodynamic
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of thrombosis. Timepoint: Efficacy of Rivaroxaban is evaluated by Doppler ultrasound conducted 30 days after drug administration. Method of measurement: Follow-up ultrasound.
- Secondary Outcome Measures
Name Time Method